Altimate Health’s SVP Medical Affairs Wins NAMI’s Researcher of the Year Award
October 1, 2021
Dr. Eden Evins, Altimate Health’s SVP of Medical Affairs and Founding Director of MGH’s Center for Addiction Medicine and Harvard Medical School Professor of Psychiatry, has won the National Alliance on Mental Illness’s Scientific Research Award for her work on smoking cessation and reducing cardiovascular risk in people with serious mental illness. The Award was established in 2013 to recognize the work of researchers who move our scientific understanding and treatment of mental illness forward.
Altimate Health, Massachusetts General Hospital Sign Agreement to Advance Precision Psychiatry
Tuesday, April 13, 2020
Altimate Health Corporation and Massachusetts General Hospital announced that they have signed a collaboration agreement for joint research, development, and commercialization in the emerging field of precision psychiatry. This is expected to lead to groundbreaking advances in the treatment of conditions including depression, substance use disorders, and serious mental illness including schizophrenia and bipolar disorder.
Dr. Maurizio Fava, Chief of Psychiatry at Massachusetts General Hospital (MGH), and a member of the scientific advisory board of Altimate, commented that “We have an opportunity to lead the development of ‘precision psychiatry’, which can account for individual differences in biology, environment and lifestyle, so we can develop more targeted and effective approaches to prevention, diagnosis, and treatment.”
“This collaboration allows us to accelerate the pace and impact of data-driven precision medicine to improve the health and well-being of people with behavioral health and psychiatric disorders”, according to Paul Pyzowski, CEO of Altimate.
According to Dr. Wasim Malik, Managing Director of Iaso Ventures, and an Altimate board member and co-founder, “The recent pandemic has brought much needed attention to the prevalence of mental illness. Digital health solutions are critical for physicians, insurers, and pharmaceutical companies to be able to address this ongoing public health crisis.”